Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2018, Article ID 8031328, 11 pages
Research Article

Fecal Galectin-3: A New Promising Biomarker for Severity and Progression of Colorectal Carcinoma

1Department of Abdominal Surgery, Military Medical Academy, Belgrade, Serbia
2Center for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia
3Department of Internal Medicine, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia
4Department of Pharmacy, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia
5Institute for Medical Research, Military Medical Academy, Belgrade, Serbia
6Department of Surgery, Faculty of Medicine Foca, University of East Sarajevo, Sarajevo, Bosnia and Herzegovina

Correspondence should be addressed to Nevena Gajovic; moc.oohay@anevencivojag

Received 29 December 2017; Revised 26 February 2018; Accepted 5 March 2018; Published 4 April 2018

Academic Editor: Amedeo Amedei

Copyright © 2018 Milan Jovanovic et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Background and Objectives. The aim of the study was to determine systemic and fecal values of galectin-3 and pro- and anti-inflammatory cytokines in patients with CRC and the relationship with clinicopathological aspects. Methods. Concentrations of galectin-3, TNF-α, TGF-β, IL-10, and IL-1β were analyzed in samples of blood and stool of 60 patients with CRC. Results. Systemic concentration of TNF-α was significantly lower in patients with severe diseases (advanced TNM stage, nuclear grade, and poor histological differentiation) as in patients with more progressive CRC (lymph and blood vessel invasion, presence of metastasis). Fecal values of anti-inflammatory cytokines TGF-β and IL-10 were increased in patients with severe stadium of CRC. Fecal concentration of Gal-3 was enhanced in CRC patients with higher nuclear grade, poor tumor tissue differentiation, advanced TNM stage, and metastatic disease. Gal-3/TNF-α ratio in sera and feces had a higher trend in patients with severe and advanced diseases. Positive correlation between fecal Gal-3 and disease severity, tumor progression, and biomarkers AFP and CEA, respectively, was also observed. Conclusions. Predomination of Gal-3 in patients with advanced diseases may implicate on its role in limiting ongoing proinflammatory processes. The fecal values of Gal-3 can be used as a valuable marker for CRC severity and progression.